Loading
A UK study following 1,000 people after bowel cancer surgery with repeated blood tests for tumour DNA, to see how well a positive predicts the cancer coming back and whether the result can guide chemotherapy.
TRACC is the Royal Marsden-led UK programme tracking ctDNA after surgery for early colorectal cancer. The registry lists it as an observational study of 1,000 participants that started on 5 December 2016, still recruiting, with a primary completion date of 31 July 2029 and study completion of 31 July 2031. It is one of the three large national colorectal programmes (with CIRCULATE-Japan and CIRCULATE-US) whose readouts decide whether ctDNA-guided adjuvant therapy becomes standard outside a trial.
Shares ALTAIR, DYNAMIC-III, CIRCULATE-US, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag ctdna-roadmap.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag ctdna-roadmap.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag ctdna-roadmap.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA) and the tag ctdna-roadmap.
Shares CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), DYNAMIC, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD).
Shares CIRCULATE-US, DYNAMIC, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD).
Shares CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), DYNAMIC, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD).
Shares DYNAMIC-III, DYNAMIC, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).